11/21
12:25 am
bcab
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing
High
Report
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing
11/14
07:08 pm
bcab
BioAtla Inc (BCAB) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Promising Trial ... [Yahoo! Finance]
High
Report
BioAtla Inc (BCAB) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Promising Trial ... [Yahoo! Finance]
11/13
06:54 pm
bcab
BioAtla outlines $800M peak sales target for Oz-V as FDA alignment paves way for phase III launch [Seeking Alpha]
High
Report
BioAtla outlines $800M peak sales target for Oz-V as FDA alignment paves way for phase III launch [Seeking Alpha]
11/13
06:52 pm
bcab
BioAtla, Inc. (BCAB) Q3 2025 Earnings Call Transcript [Seeking Alpha]
High
Report
BioAtla, Inc. (BCAB) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/7
09:00 am
bcab
BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas
Low
Report
BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas
11/5
08:00 am
bcab
BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025
Medium
Report
BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025
10/23
08:00 am
bcab
BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society
Low
Report
BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society
10/20
08:00 am
bcab
BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025
High
Report
BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025
10/3
09:45 am
bcab
BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025 [Yahoo! Finance]
Low
Report
BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025 [Yahoo! Finance]
10/3
09:00 am
bcab
BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025
Medium
Report
BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025
9/8
08:00 am
bcab
BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA
High
Report
BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA
9/6
03:31 am
bcab
High
Report